Fat Chance

“In a way, Lilly fell backward into the obesity-drug business. Soon after Chief Executive Officer David Ricks took the top job in 2017, he sent one of his top scientists, Daniel Skovronsky, on a mission to find Lilly’s most promising diabetes research. Skovronsky found a small study looking into the safety of a compound called tirzepatide, a combination of GLP-1 with another hormone. While sifting through the report, he noticed something strange. Some participants had lost so much weight while taking the drug that they dropped out of the trial.” Bloomberg (Gift Article): How a Lucky Break Fueled Eli Lilly’s $600 Billion Weight-Loss Empire.